Reviews push pet food bioactives from buzzword toward evidence

Two new review papers are adding structure to one of pet nutrition’s fastest-growing, and often murkiest, areas: functional ingredients. Rather than treating the term as a catch-all for premium positioning, the reviews frame functional ingredients and bioactive compounds as categories that should be defined by intended physiologic effect, delivery format, and actual evidence in dogs and cats. That matters as commercial pet food makers increasingly build products around claims tied to gut health, inflammation, skin and coat support, cognition, and healthy aging. (pmc.ncbi.nlm.nih.gov)

The review in Veterinary Research Communications appears aimed at bringing more consistency to the field by distinguishing among functional ingredients, bioactive compounds, and dietary supplements in companion animals, while surveying mechanisms of action and available clinical evidence. The Animals review narrows the focus to plant-derived ingredients and organizes them by phytochemical class and application form, including incorporation into complete diets and direct oral supplementation. Across both papers, the underlying message is similar: the science is expanding, but terminology, product positioning, and evidence standards haven’t always kept up. (pmc.ncbi.nlm.nih.gov)

That framing lands in a regulatory environment that is already nuanced. FDA says animal food does not fall under the human Dietary Supplement Health and Education Act framework, and substances added to pet food generally must either be approved food additives, GRAS for the intended use, or otherwise legally recognized for use in animal food. AAFCO, meanwhile, distinguishes complete-and-balanced products from treats and products intended for intermittent or supplemental feeding, and notes that ingredients and additives must have an established nutritional or technical purpose through a legally recognized process. In other words, “functional” may be a useful scientific concept, but it is not a free pass around safety, labeling, or substantiation requirements. (fda.gov)

The plant-focused review highlights the ingredient classes now familiar to many clinicians and formulators: polyphenols and plant extracts for antioxidant and anti-inflammatory activity, microalgae and omega-3 sources for lipid metabolism, cardiovascular support, and skin health, plus cannabinoids with dose-dependent effects. But the broader literature still points to uneven evidence. A 2021 review of veterinary pet supplements and nutraceuticals found that evidence quality was generally low across categories, with stronger support for omega-3 fatty acids in dogs than for many other marketed ingredients. More recent reviews also continue to describe beneficial signals for probiotics, plant extracts, and other bioactives, but often in short-duration studies, healthy animals, or narrowly defined endpoints that don’t always translate cleanly into clinical recommendations. (pmc.ncbi.nlm.nih.gov)

Industry and expert commentary has been moving in the same direction. WSAVA’s Global Nutrition Committee continues to emphasize evidence-based nutrition guidance for veterinary teams, while AAFCO’s consumer-facing materials caution that supplements and add-on products can make disease-related claims that deserve veterinary oversight. Separately, reporting in veterinary trade media has highlighted a persistent problem: the amount and quality of research vary substantially by ingredient, even as consumer demand for “natural,” “clean-label,” and health-positioned products grows. That gap between marketing momentum and clinical evidence is exactly where these new reviews are likely to get attention. (wsava.org)

Why it matters: For veterinary professionals, the real value of these reviews is less about endorsing any one ingredient and more about setting a framework for better conversations with pet parents. Many commercial diets now feature added botanicals, fibers, probiotics, algae, or other bioactives, and pet parents may reasonably assume those inclusions are clinically meaningful. Sometimes they may be. But the more useful questions in practice are whether the product is complete and balanced, whether the ingredient level and form are disclosed or supported by data, whether the intended benefit is plausible for that patient, and whether the claim belongs in food, a supplement, or drug territory. Reviews like these can help clinicians explain that promising mechanisms are not the same thing as proven outcomes, especially in cats, where evidence is often thinner. (aafco.org)

There’s also a formulation and compliance angle. As more companies build diets around targeted bioactives, scrutiny is likely to increase around ingredient definitions, allowable claims, and the line between nutritional support and implied treatment. That’s particularly relevant for ingredients such as cannabinoids, novel plant extracts, or concentrated compounds with less established regulatory footing in animal food. For clinics, that may translate into more questions about label interpretation, diet selection, adverse-event reporting, and when to steer a pet parent toward a boarded veterinary nutritionist. (fda.gov)

What to watch: The next phase will likely be less about identifying new functional ingredients and more about validating dose, format, safety, and patient-specific benefit in dogs and cats, especially through longer-term clinical studies and clearer claim substantiation standards. (pmc.ncbi.nlm.nih.gov)